CopyFind
Kenquick 500mg Tablet SR
medicine 📍 IN

Kenquick 500mg Tablet SR

21,00 ₹

Analogs of Kenquick 500mg Tablet SR

Find cheaper analogs and generic equivalents for Kenquick 500mg Tablet SR.

Ingredients

活性成分: Metformin


产品概览

About Kenquick

Kenquick is a medication containing the active ingredient Metformin, classified as Medication used to treat diabetes. Metformin, sold under the brand name Glucophage, among others, is the main first-line medication for the treatment of type 2 diabetes, particularly in people who are overweight. It is also used in the treatment of polyendocrine metabolic ovarian syndrome, and is sometimes used as an off-label adjunct to lessen the ris….

Key Benefits & Uses

  • Used for: 1 INDICATIONS AND USAGE ZITUVIMET is a combination of sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin hydrochloride (HCl), a.
  • Used for: ( 1 ) Limitations of Use: ZITUVIMET is not rec…
  • Use only as directed on the product label or by a healthcare professional.

Active Ingredient & Action

Metformin, the active ingredient in Kenquick, belongs to the Medication used to treat diabetes class. 1 INDICATIONS AND USAGE ZITUVIMET is a combination of sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use: ZITUVIMET is not rec…. Inactive ingredients: not listed in source data.

Important Notes

Always read and follow the label instructions carefully before taking Kenquick. If you have any underlying medical conditions, are taking other medicines, or are pregnant or breastfeeding, consult a doctor or pharmacist before use. Do not exceed the recommended dose on the package and do not use Kenquick for extended periods without medical advice.

Find in Pharmacies

Compare local prices and distance for Kenquick 500mg Tablet SR.

Visitor ratings

Help others by rating how useful this product page is.

No ratings yet — be the first.